{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:32:48Z","timestamp":1783571568077,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3468-1","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T14:20:04Z","timestamp":1499350804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature"],"prefix":"10.1186","volume":"17","author":[{"given":"Nobuaki","family":"Mamesaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"3468_CR1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2016.01.011","volume":"94","author":"W Zhao","year":"2016","unstructured":"Zhao W, Choi YL, Song JY, Zhu Y, Xu Q, Zhang F, et al. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Lung Cancer. 2016;94:22\u20137.","journal-title":"Lung Cancer"},{"key":"3468_CR2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1186\/1471-2407-14-786","volume":"14","author":"H Kenmotsu","year":"2014","unstructured":"Kenmotsu H, Serizawa M, Koh Y, Isaka M, Takahashi T, Taira T, et al. Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. BMC Cancer. 2014;14:786.","journal-title":"BMC Cancer"},{"key":"3468_CR3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","volume":"14","author":"T Seto","year":"2013","unstructured":"Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013;14:590\u20138.","journal-title":"Lancet Oncol"},{"key":"3468_CR4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167\u201377.","journal-title":"N Engl J Med"},{"key":"3468_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000345245","volume":"57","author":"AR Nobre","year":"2013","unstructured":"Nobre AR, Albergaria A, Schmitt F. p40: a p63 isoform useful for lung cancer diagnosis - a review of the physiological and pathological role of p63. Acta Cytol. 2013;57:1\u20138.","journal-title":"Acta Cytol"},{"key":"3468_CR6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1066896913489345","volume":"21","author":"Y Sakai","year":"2013","unstructured":"Sakai Y, Nakai T, Ohbayashi C, Imagawa N, Yanagita E, Satake R, et al. Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung. Int J Surg Pathol. 2013;21:476\u201382.","journal-title":"Int J Surg Pathol"},{"key":"3468_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3892\/mco.2016.878","volume":"5","author":"Y Yamamoto","year":"2016","unstructured":"Yamamoto Y, Kodama K, Maniwa T, Takeda M, Kishima H. Anaplastic lymphoma kinase-positive squamous cell carcinoma of the lung: a case report. Mol Clin Oncol. 2016;5:61\u20133.","journal-title":"Mol Clin Oncol"},{"key":"3468_CR8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/annonc\/mdu484","volume":"26","author":"MI Ilie","year":"2015","unstructured":"Ilie MI, Bence C, Hofman V, Long-Mira E, Butori C, Bouhlel L, et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK \u2018borderline\u2019-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol. 2015;26:238\u201344.","journal-title":"Ann Oncol"},{"key":"3468_CR9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2466-14-83","volume":"14","author":"Q Wang","year":"2014","unstructured":"Wang Q, He Y, Yang X, Wang Y, Xiao H. Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy. BMC Pulm Med. 2014;14:83.","journal-title":"BMC Pulm Med"},{"key":"3468_CR10","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.lungcan.2015.10.013","volume":"90","author":"RE Mikes","year":"2015","unstructured":"Mikes RE, Jordan F, Hutarew G, Studnicka M. First line crizotinib in anaplastic lymophoma kinase (ALK) rearranged squamous cell lung cancer. Lung Cancer. 2015;90:614\u20136.","journal-title":"Lung Cancer"},{"key":"3468_CR11","first-page":"2195","volume":"8","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Wang J, Zhang S. ALK-rearranged squamous cell lung cancer: a case report. Int J Clin Exp Pathol. 2015;8:2195\u20138.","journal-title":"Int J Clin Exp Pathol"},{"key":"3468_CR12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2015.11.010","volume":"91","author":"F Vergne","year":"2016","unstructured":"Vergne F, Qu\u00e9r\u00e9 G, Andrieu-Key S, Descourt R, Quintin-Rou\u00e9 I, Talagas M, et al. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: a missing link in the field of non-small cell lung cancer? Lung Cancer. 2016;91:67\u20139.","journal-title":"Lung Cancer"},{"key":"3468_CR13","doi-asserted-by":"crossref","unstructured":"Nokihara H, Hida T, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. J Clin Oncol. 2016;34(suppl; abstr 9008).","DOI":"10.1200\/JCO.2016.34.15_suppl.9008"},{"key":"3468_CR14","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/JTO.0000000000000575","volume":"10","author":"A Tamiya","year":"2015","unstructured":"Tamiya A, Shimizu S, Atagi S. A case of squamous cell carcinoma harboring an EML4-ALK rearrangement that was unsuccessfully treated with the ALK inhibitor alectinib. J Thorac Oncol. 2015;10:e74.","journal-title":"J Thorac Oncol"},{"key":"3468_CR15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.21037\/jtd.2016.03.96","volume":"8","author":"L Hou","year":"2016","unstructured":"Hou L, Ren S, Su B, Zhang L, Wu W, Zhang W, et al. High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma. J Thorac Dis. 2016;8:1103\u201311.","journal-title":"J Thorac Dis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3468-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T19:44:36Z","timestamp":1569699876000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3468-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3468"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3468-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]},"article-number":"471"}}